Response of mouse breast cancer cells to anastrozole, tamoxifen, and the combination

Journal of Biomedicine and Biotechnology

Volumn 2005, Issue 1, 2005, Pages 10-19

  Xanthopoulos, J M ^a   Romano, A E ^a   Majumdar, S K ^a  

^a LAFAYETTE COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CAMPTOTHECIN; TAMOXIFEN CITRATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CELL DEATH; CELL PROLIFERATION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; NONHUMAN; SCANNING ELECTRON MICROSCOPY; TREATMENT OUTCOME; TUMOR GROWTH;

MURINAE;

EID: 22544461305     PISSN: 11107243     EISSN: None     Source Type: Journal    
DOI: 10.1155/JBB.2005.10     Document Type: Article

References (37)

1. Stathopoulos GP, Malamos N, Samelis GF, et al. Long term breast cancer treatment with tamoxifen and secondary primary tumors. Eur J Cancer. 1997;33:150-152.
2. MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev. 1998;50(2):151-196.
3. Goss PE, Strasser K. Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors. Drugs. 2002;62(6):957-966.
4. Robertson JFR. Faslodex (ICI 182, 780), a novel estrogen receptor downregulator-future possibilities in breast cancer. J Steroid Biochem Mol Biol. 2001;79(1-5):209-212.
5. Coombes RC. Aromatase inhibitors and their use in the adjuvant setting. Recent Results Cancer Res. 1998;152:277-284.
6. Plourde PV, Dyroff M, Dukes M. Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat. 1994;30(1):103-111.
7. Astra Zeneca. Professional information brochure. Arimidex anastrozole tablets. August 2002:1-2.
8. Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol. 1996;14(7):2000-2011.
9. Food and Drug Administration. FDA oncology tools approval summary for anastrozole for treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Center for Drug Eval and Res. 1995, http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=156.
10. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000;18(22):3758-3767.
11. Food and Drug Administration. FDA Oncology Tools Approval Summary for anastrozole for first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. Center for Drug Eval and Res. 2000, http://www.accessdata.fda. gov/scripts/cder/onctools/summary.cfm?ID=157.
12. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359(9324):2131-2139.
13. NCI. Data support role for anastrozole as neoadjuvant therapy. Cancer Wkly. 2003;24:22.
14. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol. 2000;18(22):3748-3757.
15. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992;52(6):1399-1405.
16. Morris EJ, Geller HM. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity. J Cell Biol. 1996;134(3):757-770.
17. Kotoh T, Dhar DK, Masunaga R, et al. Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice. Surgery. 1999;125(5):536-544.
18. Ruddy JM, Majumdar SK. Antitumorigenic evaluation of thalidomide alone and in combination with cisplatin in DBA2/J mice. J Biomed Biotechnol. 2002;2(1):7-13.
19. Gad S, Weil CS. Statistics and Experimental Design for Toxicologists. 2nd ed. Caldwell, NJ: Telford Press; 1988.
20. Snedecor GW. Statistical Methods Applied to Experiments in Agriculture and Biology. 5th ed. Ames, Iowa: The Iowa State University Press; 1956.
21. NCI. FDA approval granted for Arimidex. Cancer Wkly. 2002;29:13.
22. Mokbel K. Focus on anastrozole and breast cancer. Curr Med Res Opin. 2003;19(8):683-688.
23. Lu Q, Liu Y, Long B, Grigoryev D, Gimbel M, Brodie A. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res Treat. 1999;57(2):183-192.
24. Long B, Jelovac D, Handratta V, et al. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J Natl Cancer Inst. 2004;96(6):456-465.
25. Yao K, Lee ES, Bentrem DJ, et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res. 2000;6(5):2028-2036.
26. Pulaski BA, Terman DS, Khan S, Muller E, Ostrand-Rosenberg S. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res. 2000;60(10):2710-2715.
27. Hasumi YH, Mizukami H, Urabe M, et al. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res. 2002;62(7):2019-2023.
28. Roszkowski P, Wronkowski Z, Szamborski J, Romejko M. Evaluation of selected prognostic factors in ovarian cancer. Eur J Gynaecol Oncol. 1993;14 (suppl):140-145.
29. Palencia GO, Arrieta O, Rios C, Altagracia M, Kravzov J, Sotelo J. Effect of thalidomide in different tumors in rodents. J Exp Ther Oncol. 2002;2(3):158-162.
30. Damiano J. Integrins as novel drug targets for overcoming innate drug resistance. Curr Cancer Drug Targets. 2002;2(1):37-43.
31. Karp G. Cell and Molecular Biology: Concepts and Experiments. 3rd ed. Hoboken, NJ: John Wiley & Sons; 2003.
32. Davis M, Majumdar SK. Toxic effects of raloxifene on human and mouse cancer cell lines with an emphasis on the mechanism of cell death induction. Advances in Pharmacology and Toxicology. 2001;2:17-18.
33. Shonai T, Adachi M, Sakata K, et al. MEK/ERK pathway protects ionizing radiation-induced loss of mitochondrial membrane potential and cell death in lymphocytic leukemia cells. Cell Death Differ. 2002;9(9):963-971.
34. Kimura K, Markowski M, Bowen C, Gelmann EP. Androgen blocks apoptosis of hormone-dependent prostate cancer cells. Cancer Res. 2001;61(14):5611-5618.
35. Majumdar SK, Valdellon JA, Brown KA. In vitro investigations on the toxicity and cell death induced by tamoxifen on two non-breast cancer cell types. J Biomed Biotechnol. 2001;1(3):99-107.
36. Marc CM, Majumdar SK. Scanning electron microscopy of two cancer cell types exposed to fumagillin. Journal of Electron Microscopy Society of Thailand. 2000;14(2):47-54.
37. Perry RR, Kang Y, Greaves B. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann Surg Oncol. 1995;2(3):238-245.